InnoCare Pharma (FRA:33C) Price-to-Tangible-Book : 0.98 (As of Apr. 29, 2024)

View and export this data going back to 2021. Start your Free Trial

What is InnoCare Pharma Price-to-Tangible-Book?

As of today (2024-04-29), InnoCare Pharma's share price is €0.505. InnoCare Pharma's Tangible Book per Share of Sep. 2023 for the quarter that ended in Sep. 2023 was €0.52. Hence, InnoCare Pharma's Price to Tangible Book Ratio of today is 0.98.

The historical rank and industry rank for InnoCare Pharma's Price-to-Tangible-Book or its related term are showing as below:

FRA:33C' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.01 Med: 3.27 Max: 6.55
Current: 1.01

During the past 7 years, InnoCare Pharma's highest Price to Tangible Book Ratio was 6.55. The lowest was 1.01. And the median was 3.27.

FRA:33C's Price-to-Tangible-Book is ranked better than
82.3% of 1220 companies
in the Biotechnology industry
Industry Median: 2.65 vs FRA:33C: 1.01

A closely related ratio is called PB Ratio. As of today, InnoCare Pharma's share price is €0.505. InnoCare Pharma's Book Value per Sharefor the quarter that ended in Sep. 2023 was €0.53. Hence, InnoCare Pharma's P/B Ratio of today is 0.95.

InnoCare Pharma Price-to-Tangible-Book Historical Data

The historical data trend for InnoCare Pharma's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Price-to-Tangible-Book Chart

InnoCare Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

3.12

2.79

1.47

InnoCare Pharma Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial											-	2.79	1.52	1.38	1.47

Competitive Comparison of InnoCare Pharma's Price-to-Tangible-Book

For the Biotechnology subindustry, InnoCare Pharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InnoCare Pharma's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's Price-to-Tangible-Book falls into.

InnoCare Pharma Price-to-Tangible-Book Calculation

InnoCare Pharma's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Sep. 2023 )
	=	0.505	/	0.515
	=	0.98

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

InnoCare Pharma Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (FRA:33C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

09969:Hong Kong 33C:Germany 688428:China

Address

No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206

Website

https://www.innocarepharma.com

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (FRA:33C) Headlines

No Headlines